Novo Nordisk Has Clear Lead in Oral Weight-Loss Market -- Market Talk

Dow Jones06-11 21:01

1300 GMT - Novo Nordisk's Wegovy weight-loss pill continues to perform strongly and SB1 Markets thinks the company currently has a clear lead in oral treatments for obesity, while Eli Lilly has a corresponding lead in injectable treatments. At the recent American Diabetes Association conference, Novo Nordisk confirmed that oral Wegovy has generated 3 million prescriptions since launch. "A full 82% of prescribers are new to weight management, which in our opinion shows that the oral treatment is helping to expand the market." The conference also highlighted several new studies that indirectly strengthen support for GLP-1 treatments in weight management, which might facilitate access to treatment in markets where insurance companies and authorities have so far been more restrictive, such as Sweden, SB1 Markets says. Shares fall 1% to 280.20 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

June 11, 2026 09:01 ET (13:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642282494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642282494","market":"us","top_or_hot":-1,"title":"Novo Nordisk Has Clear Lead in Oral Weight-Loss Market -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1300 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill continues to perform strongly and SB1 Markets thinks the company currently has a clear lead in oral treatments for obesity, while Eli Lilly has a corresponding lead in injectable treatments. At the recent American Diabetes Association conference, Novo Nordisk confirmed that oral Wegovy has generated 3 million prescriptions since launch. \"A full 82% of prescribers are new to weight management, which in our opinion shows that the oral treatment is helping to expand the market.\" The conference also highlighted several new studies that indirectly strengthen support for GLP-1 treatments in weight management, which might facilitate access to treatment in markets where insurance companies and authorities have so far been more restrictive, such as Sweden, SB1 Markets says. Shares fall 1% to 280.20 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 09:01 ET (13:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Has Clear Lead in Oral Weight-Loss Market -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Has Clear Lead in Oral Weight-Loss Market -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-11 21:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1300 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill continues to perform strongly and SB1 Markets thinks the company currently has a clear lead in oral treatments for obesity, while Eli Lilly has a corresponding lead in injectable treatments. At the recent American Diabetes Association conference, Novo Nordisk confirmed that oral Wegovy has generated 3 million prescriptions since launch. \"A full 82% of prescribers are new to weight management, which in our opinion shows that the oral treatment is helping to expand the market.\" The conference also highlighted several new studies that indirectly strengthen support for GLP-1 treatments in weight management, which might facilitate access to treatment in markets where insurance companies and authorities have so far been more restrictive, such as Sweden, SB1 Markets says. Shares fall 1% to 280.20 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 09:01 ET (13:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOX","symbol_name":"2倍做多NVO ETF-Defiance","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642282494","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642282494","pubTimestamp":1781182860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1300 GMT - Novo Nordisk's Wegovy weight-loss pill continues to perform strongly and SB1 Markets thinks the company currently has a clear lead in oral treatments for obesity, while Eli Lilly has a corresponding lead in injectable treatments. At the recent American Diabetes Association conference, Novo Nordisk confirmed that oral Wegovy has generated 3 million prescriptions since launch. \"A full 82% of prescribers are new to weight management, which in our opinion shows that the oral treatment is helping to expand the market.\" The conference also highlighted several new studies that indirectly strengthen support for GLP-1 treatments in weight management, which might facilitate access to treatment in markets where insurance companies and authorities have so far been more restrictive, such as Sweden, SB1 Markets says. Shares fall 1% to 280.20 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVOX":"2倍做多NVO ETF-Defiance","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"诺和诺德在口服减肥市场明显领先——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.95,"NVOH":0.6,"NVOX":0.6},"content_text":"1300 GMT - Novo Nordisk's Wegovy weight-loss pill continues to perform strongly and SB1 Markets thinks the company currently has a clear lead in oral treatments for obesity, while Eli Lilly has a corresponding lead in injectable treatments. At the recent American Diabetes Association conference, Novo Nordisk confirmed that oral Wegovy has generated 3 million prescriptions since launch. \"A full 82% of prescribers are new to weight management, which in our opinion shows that the oral treatment is helping to expand the market.\" The conference also highlighted several new studies that indirectly strengthen support for GLP-1 treatments in weight management, which might facilitate access to treatment in markets where insurance companies and authorities have so far been more restrictive, such as Sweden, SB1 Markets says. Shares fall 1% to 280.20 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 09:01 ET (13:01 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642282494","isCrawlerRequest":true}